Medicine and Dentistry
Cervical Cancer
100%
Neoplasm
54%
Radiation Therapy
48%
Positron Emission Tomography
33%
Brachytherapy
28%
Overall Survival
24%
Chemoradiotherapy
22%
Pelvis
20%
Diseases
19%
Intensity Modulated Radiation Therapy
19%
Fluorodeoxyglucose F 18
18%
Fluorodeoxyglucose
17%
Metabolism
17%
Cancer
16%
Magnetic Resonance Imaging
15%
Polyethylene Terephthalate
14%
Recurrent Disease
14%
Malignant Neoplasm
14%
Positron Emission Tomography-Computed Tomography
14%
Uterine Cervix Carcinoma
14%
High-Dose-Rate Brachytherapy
11%
Uterine Cancer
11%
Squamous Cell Carcinoma
10%
Progression Free Survival
10%
Drug Megadose
9%
External Beam Radiotherapy
9%
Cervix
8%
Standardized Uptake Value
7%
Metastatic Carcinoma
7%
Diffusion MRI
6%
Endometrium Carcinoma
6%
Intracavitary Brachytherapy
6%
Squamous Cell Carcinoma Antigen
6%
Vulva
6%
Ovarian Cancer
6%
Cancer Cell
6%
Treatment Response
6%
Biological Marker
6%
Wart Virus
5%
Radiosensitivity
5%
Keyphrases
Cervical Cancer
97%
Radiation Therapy
29%
Tumor
27%
Brachytherapy
24%
Overall Survival
23%
Intensity-modulated Radiation Therapy
19%
Cervical Cancer Patients
18%
Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)
16%
Positron Emission Tomography
16%
HDR Brachytherapy
15%
Radiotherapy
15%
Chemoradiation
14%
Cervical Carcinoma
13%
Local Control
12%
Metabolic Response
12%
Chemotherapy
11%
Squamous Cell Carcinoma Antigen
10%
18F-fluorodeoxyglucose Positron Emission Tomography (18F-FDG PET)
9%
Survival Outcomes
9%
Gynecologic Malignancies
9%
Magnetic Resonance Imaging
9%
Gene Expression
8%
Endometrial Cancer
8%
In Cancer
8%
Progression-free Survival
8%
Intracavitary Brachytherapy
7%
Standardized Uptake Value
7%
Complete Metabolic Response
7%
Clinical Outcomes
6%
High Dose
6%
Pancreatic Cancer
6%
Definitive Chemoradiation
6%
Definitive Radiotherapy
6%
Concurrent Chemotherapy
6%
Positron Emission Tomography-computed Tomography (PET-CT)
6%
Definitive Radiation
6%
External Beam Radiotherapy
6%
Tumor Response
6%
Vulvar Squamous Cell Carcinoma
6%
Locally Advanced Cervical Cancer
6%
Tumor Immunity
6%
Improved Survival
6%
High-risk Human Papillomavirus (HR-HPV)
5%
Fluorodeoxyglucose Positron Emission Tomography/computed Tomography
5%
Confidence Interval
5%
Ovarian Cancer
5%
Chemoradiotherapy
5%
Pancreatic Ductal Adenocarcinoma
5%
Invasive Cervical Cancer
5%
18F-fluorodeoxyglucose (18F-FDG)
5%